{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:08:11Z","timestamp":1761948491030,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12872-019-1042-2","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T14:03:18Z","timestamp":1552658598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: a meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-3031","authenticated-orcid":false,"given":"Alberto","family":"Polimeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remzi","family":"Anadol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Indolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1093\/eurheartj\/ehv391","volume":"37","author":"AR Galassi","year":"2016","unstructured":"Galassi AR, Brilakis ES, Boukhris M, et al. Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview. Eur Heart J. 2016;37:2692\u2013700.","journal-title":"Eur Heart J"},{"key":"1042_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jcin.2012.01.012","volume":"5","author":"DA Jones","year":"2012","unstructured":"Jones DA, Weerackody R, Rathod K, et al. Successful recanalization of chronic total occlusions is associated with improved long-term survival. JACC Cardiovasc Interv. 2012;5:380\u20138.","journal-title":"JACC Cardiovasc Interv."},{"key":"1042_CR3","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/j.jcin.2017.09.008","volume":"10","author":"M Roffi","year":"2017","unstructured":"Roffi M, Iglesias JF. CTO PCI in patients with diabetes mellitus: sweet perspectives. JACC Cardiovasc Interv. 2017;10:2182\u20134.","journal-title":"JACC Cardiovasc Interv."},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijcard.2017.01.058","volume":"247","author":"V Dinesch","year":"2017","unstructured":"Dinesch V, Buruian M. Drug-eluting stent failure: A complex scenario. Int J Cardiol. 2017;247:26.","journal-title":"Int J Cardiol"},{"key":"1042_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrcardio.2016.151","volume":"13","author":"C Indolfi","year":"2016","unstructured":"Indolfi C, De Rosa S, Colombo A. Bioresorbable vascular scaffolds - basic concepts and clinical outcome. Nat Rev Cardio. 2016;13:719\u201329.","journal-title":"Nat Rev Cardio"},{"key":"1042_CR6","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","volume":"66","author":"R Gao","year":"2015","unstructured":"Gao R, Yang Y. Han yet al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol. 2015;66:2298\u2013309.","journal-title":"J Am Coll Cardiol"},{"key":"1042_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.4244\/EIJY16M09_01","volume":"12","author":"Y Onuma","year":"2016","unstructured":"Onuma Y, Sotomi Y, Shiomi H, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12:1090\u2013101.","journal-title":"EuroIntervention"},{"key":"1042_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.4244\/EIJY16M08_01","volume":"12","author":"B Chevalier","year":"2016","unstructured":"Chevalier B, Onuma Y, van Boven AJ, et al. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention. 2016;12:1102\u20137.","journal-title":"EuroIntervention."},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa1614954","volume":"376","author":"JJ Wykrzykowska","year":"2017","unstructured":"Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376:2319\u201328.","journal-title":"N Engl J Med"},{"key":"1042_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72:39.","journal-title":"Arch Public Health"},{"key":"1042_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2217\/cer.13.17","volume":"2","author":"BC Wallace","year":"2013","unstructured":"Wallace BC, Dahabreh IJ, Schmid CH, Lau J, Trikalinos TA. Modernizing the systematic review process to inform comparative effectiveness: tools and methods. J Comp Eff Res. 2013;2:273\u201382.","journal-title":"J Comp Eff Res"},{"key":"1042_CR12","doi-asserted-by":"publisher","first-page":"E155","DOI":"10.1002\/ccd.26397","volume":"88","author":"A Manna La","year":"2016","unstructured":"La Manna A, Chisari A, Giacchi G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: technical and procedural outcomes from the GHOST-CTO registry. Catheter Cardiovasc Interv. 2016;88:E155\u201363.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1042_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.amjcard.2015.02.048","volume":"115","author":"S Ojeda","year":"2015","unstructured":"Ojeda S, Pan M, Romero M, et al. Outcomes and computed tomography scan follow-up of bioresorbable vascular scaffold for the percutaneous treatment of chronic total coronary artery occlusion. Am J Cardiol. 2015;115:1487\u201393.","journal-title":"Am J Cardiol"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijcard.2014.10.032","volume":"179","author":"J Wiebe","year":"2015","unstructured":"Wiebe J, Liebetrau C, D\u00f6rr O, et al. Feasibility of everolimuseluting bioresorbable vascular scaffolds in patients with chronic total occlusion. Int J Cardiol. 2015;179:90\u20134.","journal-title":"Int J Cardiol"},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.amjcard.2015.12.025","volume":"117","author":"B Vaquerizo","year":"2016","unstructured":"Vaquerizo B, Barros A, Pujadas S, et al. One-year results of bioresorbable vascular scaffolds for coronary chronic total occlusions. Am J Cardiol. 2016;117:906\u201317.","journal-title":"Am J Cardiol"},{"key":"1042_CR16","doi-asserted-by":"publisher","unstructured":"Azzalini L, Giustino G, Ojeda S, et al. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions). Circ Cardiovasc Interv. 2016;9(10). \n                    https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.116.004284\n                    \n                  .","DOI":"10.1161\/CIRCINTERVENTIONS.116.004284"},{"key":"1042_CR17","doi-asserted-by":"publisher","unstructured":"Abellas-Sequeiros RA, Ocaranza-Sanchez R, Trillo-Nouche R, Gonzalez-Juanatey C, Gonzalez-Juanatey JR. Bioresorbable vascular scaffolds in coronary chronic total occlusions revascularization: safety assessment related to struts coverage and apposition in 6-month OCT follow-up. Heart Vessel. 2017. \n                    https:\/\/doi.org\/10.1007\/s00380-017-0980-9\n                    \n                  .","DOI":"10.1007\/s00380-017-0980-9"},{"key":"1042_CR18","doi-asserted-by":"publisher","unstructured":"Mitomo S, Naganuma T, Fujino Y, et al. Bioresorbable Vascular Scaffolds for the Treatment of Chronic Total Occlusions: An International Multicenter Registry. Circ Cardiovasc Interv. 2017;10. \n                    https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.116.004265\n                    \n                  .","DOI":"10.1161\/CIRCINTERVENTIONS.116.004265"},{"key":"1042_CR19","first-page":"647","volume":"44","author":"AH Yama\u00e7","year":"2016","unstructured":"Yama\u00e7 AH, Y\u0131ld\u0131z A, Nasifov M, Ta\u015ftan A, Bashirov N, G\u00f6ktekin \u00d6. Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. Turk Kardiyol Dern Ars. 2016;44:647\u201355.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"1042_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MCA.0000000000000449","volume":"28","author":"C Kugler","year":"2017","unstructured":"Kugler C, Markovic S, Rottbauer W, W\u00f6hrle J. Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison. Coron Artery Dis. 2017;28:120\u20135.","journal-title":"Coron Artery Dis"},{"key":"1042_CR21","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.4244\/EIJV12I2A27","volume":"12","author":"M Lesiak","year":"2016","unstructured":"Lesiak M, \u0141anocha M, Araszkiewicz A, et al. Percutaneous coronary intervention for chronic total occlusion of the coronary artery with the implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry. EuroIntervention. 2016;12:e144\u201351.","journal-title":"EuroIntervention"},{"key":"1042_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5830\/CVJA-2016-033","volume":"27","author":"E \u00d6zel","year":"2016","unstructured":"\u00d6zel E, Ta\u015ftan A, \u00d6zt\u00fcrk A, \u00d6zcan EE, Kilicaslan B, \u00d6zdogan \u00d6. Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-Centre experience. Cardiovasc J Afr. 2016;27:345\u20139.","journal-title":"Cardiovasc J Afr"},{"key":"1042_CR23","first-page":"461","volume":"27","author":"O Goktekin","year":"2015","unstructured":"Goktekin O, Yamac AH, Latib A, et al. Evaluation of the safety of Everolimus-eluting Bioresorbable vascular scaffold (BVS) implantation in patients with chronic Total coronary occlusions: acute procedural and short-term clinical results. J Invasive Cardiol. 2015;27:461\u20136.","journal-title":"J Invasive Cardiol"},{"key":"1042_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4244\/EIJ-D-16-00253","volume":"13","author":"JM Fam","year":"2017","unstructured":"Fam JM, Ojeda S, Garbo R, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions. EuroIntervention. 2017;13:355\u201363.","journal-title":"EuroIntervention."},{"key":"1042_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/joic.12297","volume":"29","author":"M Saad","year":"2016","unstructured":"Saad M, Abdin A, Thiele H, et al. Bioresorbable vascular scaffolds in a real-world patient population-results from a mid-term angiographic follow-up. J Interv Cardiol. 2016;29:341\u20137.","journal-title":"J Interv Cardiol"},{"key":"1042_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12872-017-0586-2","volume":"17","author":"A Polimeni","year":"2017","unstructured":"Polimeni A, Anadol R, Munzel T, Indolfi C, De Rosa S, Gori T. Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs. BMC Cardiovasc Disord. 2017;17:147.","journal-title":"BMC Cardiovasc Disord"},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1016\/j.jacc.2017.04.011","volume":"69","author":"S Sorrentino","year":"2017","unstructured":"Sorrentino S, Giustino G, Mehran R, et al. Everolimus-eluting Bioresorbable scaffolds versus Everolimus-eluting metallic stents. J Am Coll Cardiol. 2017;69:3055\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1042_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","volume":"387","author":"GW Stone","year":"2016","unstructured":"Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387:1277\u201389.","journal-title":"Lancet."},{"key":"1042_CR29","first-page":"1101","volume":"19","author":"SS Yang","year":"2015","unstructured":"Yang SS, Tang L, Ge GG, et al. Efficacy of drug-eluting stent for chronic total coronary occlusions at different follow-up duration: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2015;19:1101\u201316.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1042_CR30","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.jacc.2009.12.038","volume":"55","author":"HJ Colmenarez","year":"2010","unstructured":"Colmenarez HJ, Escaned J, Fern\u00e1ndez C, et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1854\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1042_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ahj.2018.07.013","volume":"204","author":"S Brugaletta","year":"2018","unstructured":"Brugaletta S, Gomez-Lara J, Caballero J, et al. Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: a randomized clinical trial. Am Heart J. 2018;204:205\u20139.","journal-title":"Am Heart J"},{"key":"1042_CR32","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jcin.2017.07.034","volume":"10","author":"A Polimeni","year":"2017","unstructured":"Polimeni A, Weissner M, Schochlow K, et al. Incidence, clinical presentation, and predictors of clinical restenosis in coronary Bioresorbable scaffolds. JACC Cardiovasc Interv. 2017;10:1819\u201327.","journal-title":"JACC Cardiovasc Interv"},{"key":"1042_CR33","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ijcard.2015.11.086","volume":"203","author":"A Polimeni","year":"2016","unstructured":"Polimeni A, De Rosa S, Sabatino J, Sorrentino S, Indolfi C. Impact of intracoronary adenosine administration during primary PCI: a meta-analysis. Int J Cardiol. 2016;203:1032\u201341.","journal-title":"Int J Cardiol"},{"key":"1042_CR34","doi-asserted-by":"crossref","first-page":"e004613","DOI":"10.1161\/CIRCINTERVENTIONS.116.004613","volume":"11","author":"S Rosa De","year":"2018","unstructured":"De Rosa S, Polimeni A, Petraco R, Davies JE, Indolfi C. Diagnostic performance of the instantaneous wave-free ratio: comparison with fractional flow reserve. Circ Cardiovasc Interv. 2018;11:e004613.","journal-title":"Circ Cardiovasc Interv"},{"key":"1042_CR35","doi-asserted-by":"publisher","unstructured":"De Rosa S, Sievert H, Sabatino J, Polimeni A, Sorrentino S, Indolfi C. Percutaneous closure versus medical treatment in stroke patients with patent foramen Ovale: a systematic review and meta-analysis. Ann Intern Med. 2018. \n                    https:\/\/doi.org\/10.7326\/M17-3033\n                    \n                  .","DOI":"10.7326\/M17-3033"},{"key":"1042_CR36","doi-asserted-by":"publisher","unstructured":"Anadol R, Lorenz L, Weissner M, et al. Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds Three years follow-up in a cohort of consecutive patients. EuroIntervention. 2017. \n                    https:\/\/doi.org\/10.4244\/EIJ-D-17-00410\n                    \n                  .","DOI":"10.4244\/EIJ-D-17-00410"},{"key":"1042_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12872-018-0811-7","volume":"18","author":"R Anadol","year":"2018","unstructured":"Anadol R, Schnitzler K, Lorenz L, et al. Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds. BMC Cardiovasc Disord. 2018;18:92.","journal-title":"BMC Cardiovasc Disord"},{"key":"1042_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/CH-189101","volume":"69","author":"R Anadol","year":"2018","unstructured":"Anadol R, Dimitriadis Z, Polimeni A, et al. Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: a three-years follow-up1. Clin Hemorheol Microcirc. 2018;69:3\u20138.","journal-title":"Clin Hemorheol Microcirc"},{"key":"1042_CR39","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jcin.2017.08.020","volume":"10","author":"T Gori","year":"2017","unstructured":"Gori T, Weissner M, G\u00f6nner S, et al. Characteristics, predictors, and mechanisms of thrombosis in coronary Bioresorbable scaffolds: differences between early and late events. JACC Cardiovasc Interv. 2017;10:2363\u201371.","journal-title":"JACC Cardiovasc Interv."},{"key":"1042_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijcard.2016.01.202","volume":"208","author":"S Biscaglia","year":"2016","unstructured":"Biscaglia S, Ugo F, Ielasi A, Secco GG, Durante A, D'Ascenzo F, et al. Bioresorbable scaffold vs. second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study). Int J Cardiol. 2016;208:40\u20135.","journal-title":"Int J Cardiol"},{"key":"1042_CR41","doi-asserted-by":"publisher","unstructured":"Gori T; Polimeni A; Adriaenssen T et al. Predictors of stent thrombosis and their implications for clinical practice. Nat. Rev. Cardiol.; 2018;In press. \n                    https:\/\/doi.org\/10.1038\/s41569-018-0118-5\n                    \n                  .","DOI":"10.1038\/s41569-018-0118-5"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-1042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-019-1042-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-1042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:12:03Z","timestamp":1584144723000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-019-1042-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1186\/s12872-019-1042-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"19 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"59"}}